<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Transfusion-induced <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> is a frequent problem that clinicians have to face in the treatment of patients affected by both <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (PMF) </plain></SENT>
<SENT sid="1" pm="."><plain>Different options are currently available for chelation therapy, e.g. oral once-daily administration of the iron <z:chebi fb="0" ids="38161">chelator</z:chebi> <z:chebi fb="0" ids="49005">deferasirox</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>In 3 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 1 patient with PMF, <z:chebi fb="0" ids="49005">deferasirox</z:chebi> therapy resulted in an improvement in the <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level and a reduction in transfusion dependence </plain></SENT>
<SENT sid="3" pm="."><plain>Our data open new insights regarding the benefit of iron chelation therapy not only for transfusional <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> of myelodysplastic and myelofibrotic patients but also for the increase in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> levels </plain></SENT>
<SENT sid="4" pm="."><plain>The biological mechanism of action of <z:chebi fb="0" ids="49005">deferasirox</z:chebi>, an effect which is not shared by other iron <z:chebi fb="0" ids="38161">chelators</z:chebi>, is still obscure and requires further investigations </plain></SENT>
</text></document>